Prevention and treatment of infection by West Nile virus (WNV) and other flaviviruses are public health priorities. We describe a reporting cell line that can be used for high-throughput screening of inhibitors against all targets involved in WNV replication. Dual reporter genes, encoding Renilla luciferase (Rluc) and neomycin phosphotransferase (Neo), were engineered into a WNV subgenomic replicon, resulting in Rluc/NeoRep. Geneticin selection of BHK-21 cells transfected with Rluc/NeoRep yielded a stable cell line that contains persistently replicating replicons. Incubation of the reporting cells with known WNV inhibitors decreased Rluc activity, as well as the replicon RNA level. The efficacies of the inhibitors, as measured by the depression of Rluc activity in the reporting cells, are comparable to those derived from authentic viral infection assays. Therefore, the WNV reporting cell line can be used as a high-throughput assay for anti-WNV drug discovery. A similar approach should be applicable to development of genetics-based antiviral assays for other flaviviruses.
Many flaviviruses are significant human pathogens, including the four serotypes of dengue virus, yellow fever virus, Japanese encephalitis virus, tick-borne encephalitis virus, St. Louis encephalitis virus, and West Nile virus (WNV) (7) . Flavivirus virions are spherical in shape with a diameter of 40 to 60 nm. The nucleocapsid of about 30 nm in diameter consists of capsid and genomic RNA and is surrounded by a lipid bilayer in which the viral envelope and membrane proteins are embedded (5) . The flavivirus genome is a single-stranded RNA of positive polarity, approximately 11 kb in length. The genomic RNA contains a 5Ј untranslated region (5Ј UTR), a single open reading frame (ORF), and a 3Ј UTR (Fig. 1A) . The ORF encodes 10 viral proteins: three structural (capsid [C] , premembrane [prM] or membrane [M] , and envelope [E]) proteins and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) proteins (6) . The nonstructural proteins are primarily involved in viral replication. NS1 and its potential interaction with NS4A are required for RNA replication (26, 27) . The hydrophobic NS2A was recently shown to function during virion assembly and release of infectious viral particles (24) . NS2B forms a complex with NS3 and is a required cofactor for the serine protease function of NS3 (2, 9, 11, 17) . NS3 is a multifunctional protein which exhibits enzymatic activities of a serine protease (in the presence of NS2B), 5Ј-RNA triphosphatase, NTPase, and helicase (3, 5, 25, (39) (40) (41) . The functions of the membrane-associated NS4A and NS4B are not known. NS5 contains activities of an RNA-dependent RNA polymerase (RdRp) (1, 18, 38) and a methyltransferase (16, 23) . Upon flavivirus infection, the plus-sense genomic RNA is transcribed into a complementary minus-sense RNA, which in turn serves as the template for the synthesis of more plus-sense genomic RNA (10, 15, 31, 35) . The synthesis of plus-and minus-sense RNAs is asymmetric; plus-sense RNA is produced in 10-to 100-fold excess over minus-sense RNA (15, 31, 35) .
WNV was originally isolated in 1937 from the blood of a febrile patient in the West Nile district of northern Uganda (37) and was subsequently found in many other regions, including additional areas of Africa, the Middle East, Europe, Russia, India, Indonesia, and, most recently, North America (7). Since its appearance in the United States in 1999, WNV has caused significant human, equine, and avian disease and has resulted in over 4,156 known human cases, including at least 284 human deaths (for updates, see http://www.cdc.gov /ncidod/dvbid/westnile/surv&controlCaseCount03.htm). The WNV epidemic in the United States in 2002 represents the largest meningoencephalitis outbreak in the Western Hemisphere and the largest WNV outbreak ever reported (8) . Neither a vaccine nor an effective therapy for WNV infection in humans is available, although inactivated-WNV-and DNAbased vaccines have been developed for use in equines (13, 29) . It is therefore a public health priority to develop effective means of prevention and treatment of WNV infections.
Development of high-throughput assays is essential for antiviral drug discovery. The present antiviral assay for WNV is based on viral infection of cultured cells, followed by monitoring of compound inhibition of viral replication through observation or quantification of cytopathic effects, or quantification of viral RNA by reverse transcription-PCR (RT-PCR) (20, 30) . The low-throughput nature of the viral infection assay limits its use for efficiently screening compound libraries. The recent establishment of genetic systems of WNV (35, 36, 43) has provided foundations for the development of novel antiviral assays. Here we report a stable cell line that can be used for high-throughput screening of inhibitors of WNV replication.
We previously reported that a subgenomic replicon of WNV, containing a large in-frame deletion (from nucleotides [nt] 190 to 2379 as indicated by dashed lines in Fig. 1A ) of the C-prM-E structural region, replicates efficiently in BHK-21 cells (35) . The replicon retained the N-terminal 31 amino acids (nt 97 to 189) of the C protein and the C-terminal 30 amino acids of the E protein (nt 2380 to 2469), to preserve a replication cis element (also known as the cyclization sequence) (19, 21, 44) and the correct processing and translocation of the remaining nonstructural polyprotein in the correct topology across the membrane of the endoplasmic reticulum (10), respectively. To develop a high-throughput antiviral assay, we engineered two reporter genes, Renilla luciferase (Rluc) and neomycin phosphotransferase (Neo), into the original WNV replicon, resulting in Rluc/NeoRep (Fig. 1A) . Translation of the Neo gene was driven by an encephalomyocarditis virus internal ribosomal entry site (IRES) in the upstream end of the 3Ј UTR of the replicon. To prepare the IRES-Neo fragment, we amplified individual IRES and Neo through PCR from plasmid pIRES2-GFP (Clontech, Palo Alto, Calif.) and pcDNA3.1 (Invitrogen, Carlsbad, Calif.), using primer F-IRES and R-IRES and primers F-Neo and R-Neo, respectively (Table 1). Fragments of IRES and Neo were then fused to yield IRES-Neo through overlapping PCR (32) . The fused IRESNeo was inserted into the NsiI site (nt 10436) in the 3Ј UTR of the original replicon. Next, the Rluc gene was PCR amplified from plasmid pRL-SV40 (Promega, Madison, Wis.) using primer F-Rluc and R-Rluc (Table 1 ) and then fused in frame into the AflII site of the replicon (35) . The Rluc gene was selected as a reporter for assay development because of its relatively small size (936 bp) and its robust enzymatic activity.
To test whether the dual reporting replicon is replication competent, Rluc/NeoRep RNA was in vitro transcribed and transfected into BHK-21 cells as previously described (35, To establish a stable cell line containing a persistently replicating dual reporting replicon, we transfected BHK-21 cells with the Rluc/NeoRep and selected the transfected cells under Geneticin (G418). Briefly, approximately 8 ϫ 10 6 BHK-21 cells were electroporated with 10 g of Rluc/NeoRep RNA at settings previously described (36) , recovered in cuvettes for 10 min, resuspended in 50 ml of Dulbecco modified Eagle medium (DMEM) containing 10% fetal bovine serum (FBS), and transferred to a T-150 flask. After an overnight recovery, the cells were subjected to G418 selection (1 mg/ml) in DMEM with 10% FBS. Medium was replaced every 2 to 3 days with fresh G418. After 10 days of selection, the majority of the cells died, presumably because these cells were untransfected or because they expressed an insufficient amount of Neo. However, many surviving cells were observed. Individual foci were cloned, expanded, and stored in 10% dimethyl sulfoxide (DMSO) and 40% FBS in liquid nitrogen. Cells were continually passaged under G418 selection for over 80 days (over 25 passages).
To test the stability of the replicon-containing cell lines, cells a The primers were named according to their polarity (F, forward sense primer; R, reverse antisense primer) followed by the name of the amplified fragment (IRES, Neo, or Rluc).
b Sequences from IRES, Neo, Rluc, or WNV are in uppercase letters. Extra tail sequences to facilitate restriction enzyme digestion are in lowercase letters. Restriction endonuclease sites are underlined and indicated in parentheses. (Fig. 1D) . Real-time RT-PCR, targeting the viral NS1 region, was used to quantify replicon RNA as previously reported (34, 35) . Total RNA extracted from 10 6 cells was eluted in 50 l of RNase-free water using RNeasy kits (Qiagen); 5 l of RNA was quantified by real-time RT-PCR, using in vitro-transcribed RNA as standards. We estimated 10 To examine whether the reporting cell line can be used as an antiviral assay, we tested three known WNV inhibitors in the cells: 6-azauridine, an inhibitor of orotidine monophosphate decarboxylase, and mycophenolic acid and ribavirin, inhibitors of IMP dehydrogenase (14, 20, 30) . Ribavirin has also been reported to function as a mutagen, causing lethal levels of mutagenesis within the virus population (12) . All three compounds were purchased from Sigma (St. Louis, Mo.). Initially, we performed the assay in 12-well plates. Approximately 2.5 ϫ 10 5 cells were seeded into each well, containing DMEM with 2.5% FBS (without G418). Compounds were dissolved in DMSO and added to cells at various concentrations in medium with a final DMSO concentration of 1%. Cells not treated with compounds were still treated with 1% DMSO as a negative control. After 24 h of compound treatment at 37°C, cells were assayed for Rluc activity. As shown in Fig. 2A , the Rluc activity decreased with increasing concentration of each compound. Based on the Rluc curves, the EC 50 s (the compound concentration required to inhibit 50% of the Rluc activity) were estimated to be 5.4, 11, and 140 M for mycophenolic acid, 6-azauridine, and ribavirin, respectively. These EC 50 s correlate well with the EC 50 s derived from the standard viral infection assay (8.4, 6.1, and 178 M, respectively) (30) . Longer (48-h) or shorter (12-h) treatment of the cells with the same compounds yielded EC 50 s severalfold higher than those obtained with the 24-h incubation (data not shown). One of the major differences between the replicon-containing cell assay (described here) and the standard viral infection assay is that, in the replicon-containing cell assay, the compound is added to cells inside which replicon RNAs are already under full replication, whereas in the standard viral infection assay, compound can be added either simultaneously or prior to viral infection of cells. In the replicon-containing cell assay, the Rluc signal is determined by multiple factors, including the doubling time of the replicon-containing cells (approximately 12 to 16 h), the potency and stability of the tested compound, the stability of replicon RNA, and the half-life of Rluc enzyme (about 3 to 6 h; Promega). As a consequence of these combinatory factors, at 12 h post-compound treatment, although the compound may start to inhibit replicon replication, the preexisting Rluc enzyme has not decayed to a level low enough to show a dramatic inhibitory effect of the compound. At 48 h post-compound treatment, the replicon-containing cells have doubled three to four times; if the inhibitory effect of the compound could not outcompete the increase of replicon RNA resulting from the cell number increase, the sensitivity of the assay would decrease, thereby increasing the EC 50 s of the tested compounds. The experimental results clearly showed that incubation of the cells with compound for 24 h yields the highest assay sensitivity. To increase the throughput of the assay, we performed the experiments in a 96-well format with approximately 5 ϫ 10 4 cells seeded into each well; similar results as described above were obtained (data not shown). These results indicated that the Rluc activity from the cell line could be used for screening inhibitors of WNV in a high-throughput fashion.
Next, we performed real-time RT-PCR to verify that the reduction in Rluc activity reflected the compound inhibition of viral RNA replication. After 24 h of compound treatment, cells from the 12-well plates were assayed for RNA amounts as described above, except that 12 l from the 50-l extracted RNA was used in the real-time RT-PCR assay. Similar to the Rluc results, decreasing amounts of replicon RNA were observed with increasing concentrations of inhibitor (Fig. 2B) . The relative potencies of the three tested compounds are also similar to those observed with the Rluc results, in the decreasing order of mycophenolic acid, 6-azauridine, and ribavirin (compare Fig. 2A to B) . However, the EC 50 s derived from the RNA copy numbers were much larger than those derived from the Rluc activity results: approximately 100 M for mycophenolic acid and more than 300 M for 6-azauridine and ribavirin (Fig. 2B) . The higher sensitivity of the Rluc-based assay than that of the RNA copy-based assay is likely due to enzymatic signal amplification by the Rluc. Finally, to exclude the possibility that the reduction of Rluc activity and viral RNA copy number was due to cytotoxicity of the compounds, we performed an XTT [2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, a substrate for mitochondrial dehydrogenase used for determination of cell viability] assay on parental BHK-21 cells (20) . In accordance with previous reports (20, 30) , no toxicity was observed at 300 M for any of the three compounds (data not shown). Overall, the above results demonstrated that the Rluc activity reflects the replication level of viral RNA inside the cells and that the reporting cell line can serve as a high-throughput assay for screening inhibitors of WNV replication.
Replicon-based cell lines have been previously reported for a number of flaviviruses, including Kunjin virus (22) , hepatitis C virus (4, 28) , and WNV (35) . The novel antiviral assay described here serves as a proof-of-principle that a similar approach should be applicable to development of geneticsbased antiviral assays for other flaviviruses (33) . The repliconbased assay covers all targets during viral replication, including viral translation, and plus-and minus-sense RNA synthesis. However, because no structural genes and, therefore, no infectious viral particles are involved in the replicon system, the assay does not include targets involved in viral entry, genome encapsidation, and virion maturation. On the other hand, because no infectious virions are formed, the replicon-based assay can be performed in a biosafety level 2 laboratory, rather than in a biosafety level 3 containment chamber. One other advantage of the replicon-cell line assay is that inhibitors identified through such a cell-based assay should have a high success rate in subsequent animal experiments because the assay tests the cellular uptake of compounds and, potentially, the stability of the compounds inside the cells (33) .
Since Rluc is the reporter for the system, the assay may select potential inhibitors of the Rluc enzyme rather than inhibitors of viral replication. Rluc inhibitors can be quickly eliminated by testing any hits derived from the replicon-based screening in a recombinant Rluc assay (Chemicon International, Temecula, Calif.). The mode of action of viral inhibitors can be identified through individual biochemical assays such as RdRp, protease, NTPase, or helicase activity. Alternatively, the mode of action of the compounds could be analyzed through selection of compound-resistant virus followed by mapping of the mutated gene(s) and back-engineering of specific mutations into an infectious clone for phenotypic verification. The full-length infectious clone of WNV (36, 43) and recombinant systems of WNV NS5 RdRp and NS3 NTPasehelicase (42) will facilitate these analyses.
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